Insider Transactions in Q3 2024 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
79,616
-3.18%
|
$716,544
$9.19 P/Share
|
|
Aug 14
2024
|
Erick Gamelin Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
402
-2.26%
|
$2,814
$7.02 P/Share
|
|
Aug 14
2024
|
Rasmus Holm Jorgensen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-1.35%
|
$2,576
$7.02 P/Share
|
|
Aug 14
2024
|
Kristina Masson EVP - Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
490
-0.15%
|
$3,430
$7.02 P/Share
|
|
Aug 14
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
184
-0.47%
|
$1,288
$7.02 P/Share
|
|
Aug 14
2024
|
Katharine Peterson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.09%
|
$693
$7.02 P/Share
|
|
Aug 14
2024
|
Peter Blume Jensen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
59,765
-2.33%
|
$418,355
$7.02 P/Share
|
|
Aug 14
2024
|
Eric Devroe Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
613
-0.89%
|
$4,291
$7.02 P/Share
|
|
Jul 17
2024
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.41%
|
$3,906
$7.69 P/Share
|